<DOC>
	<DOCNO>NCT00091858</DOCNO>
	<brief_summary>The purpose study evaluate efficacy darbepoetin alfa versus placebo reduce occurrence red blood cell transfusion subject anemia cancer receive chemotherapy .</brief_summary>
	<brief_title>Study Darbepoetin Alfa Treatment Anemia Cancer</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>subject nonmyeloid malignancy anemia due cancer ECOG status 0 2 great equal 4month expectancy great equal 18 year legal age inform consent screen hemoglobin concentration less equal 11.0g/dL adequate serum folate vitamin B12 adequate renal liver function write informed consent subject currently receive plan receive cytotoxic chemotherapy myelosuppressive radiotherapy study within 4 week randomization complete remission , determine investigator subject diagnose related cancer cause anemia ( eg . gastrointestinal bleeding , renal disease , etc ) document history pure red cell aplasia Known history seizure disorder cardiac condition : uncontrolled angina , congestive heart failure , know ejection fraction le 40 % , uncontrolled cardiac arrhythmia uncontrolled hypertension clinically significant systemic infection chronic inflammatory disease present time randomization iron deficiency know positive test HIV infection previously suspect confirmed neutralizing antibody rHuEPO darbepoetin alfa receive rHuEPO darbepoetin alfa therapy within 4 week randomization le 30 day since receipt investigational drug device approve applicable regulatory authority pregnant breast feeding subject reproductive potential use adequate contraceptive precaution know hypersensitivity mammalianderived product ingredient investigational product previously randomize study concern subject 's compliance protocol procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Cancer-related anemia</keyword>
</DOC>